Ventricular Fibrillation

Overview
Mechanisms and Initiation
Underlying Substrates and Causes
Chain of Survival
CPR Technique
Defibrillation and ACLS
Post-ROSC Care
ICD Therapy and Long-term Management
Prognosis and Neurological Outcomes
Key Research Papers
Connections
Featured Videos

Overview

Ventricular fibrillation (VF) is the most dangerous cardiac arrhythmia — a state of completely disorganized, chaotic electrical activity in the ventricles that abolishes coordinated mechanical contraction. Without the synchronized squeeze of the heart muscle, the ventricles quiver uselessly and cardiac output falls to zero. The result is cardiac arrest: loss of pulse, loss of consciousness, and brain death beginning within 4 to 6 minutes if no intervention occurs. Survival without defibrillation approaches zero after 10 minutes.

VF is the most common rhythm found on the first ECG recorded during sudden cardiac death (SCD), accounting for approximately 80% of sudden cardiac arrests in adults. On the electrocardiogram it appears as a completely disorganized wavy baseline with no recognizable P waves, QRS complexes, or T waves. "Coarse" VF — with larger amplitude deflections — is generally more responsive to defibrillation than "fine" VF, which may reflect deeper ischemia or prolonged cardiac arrest.

It is important to distinguish VF from ventricular tachycardia (VT). VT has discrete, organized QRS complexes (even if wide and abnormal) and may maintain some degree of cardiac output. VF has no organized complexes at all. Rapid VT can degenerate into VF, and the two are managed along a shared continuum in advanced cardiac life support.

Clinicians classify VF as primary (arising without detectable structural heart disease, as in idiopathic VF or channelopathies) or secondary (occurring on the background of identifiable structural disease such as ischemic cardiomyopathy or hypertrophic cardiomyopathy). This distinction matters for long-term risk stratification and the choice of preventive therapy.

Back to Table of Contents

Mechanisms and Initiation

VF requires two components to arise: a trigger that initiates the episode, and a vulnerable substrate in the myocardium that allows chaotic activity to self-perpetuate.

The most common trigger is a premature ventricular complex (PVC) that fires during the vulnerable period of cardiac repolarization — the peak of the T wave on the ECG. This is called the R-on-T phenomenon. During the T wave, different regions of the myocardium are in different phases of repolarization; a well-timed electrical stimulus falling during this window finds some cells ready to depolarize and others still refractory, creating the spatial heterogeneity needed to launch re-entrant circuits.

Electrical heterogeneity is the key substrate concept. When neighboring myocardial cells have substantially different refractory periods — due to ischemia, fibrosis, ion channel mutations, or electrolyte disturbances — a wavefront of activation can travel through recovered tissue, circle back to re-excite tissue that has just recovered, and sustain a re-entrant loop. Two major theories describe how VF perpetuates itself once started:

Multiple wavelet hypothesis (Moe, 1960s): VF is maintained by multiple simultaneously circulating wavelets, each independently re-entering available tissue. The wavelets break up, collide, and re-form in a chaotic, self-sustaining pattern. The minimum substrate required is roughly 20–30 wavelets simultaneously present in the ventricles.
Rotor/spiral wave theory (more contemporary): A single stable, high-frequency rotating wavefront — a "rotor" — anchored to a site of heterogeneous tissue drives the rest of the myocardium into fibrillatory conduction. Breakthroughs from the rotor appear as chaotic activity in the rest of the heart. This theory supports the rationale for ablating the rotor source in refractory VF.

Beyond re-entry, calcium handling abnormalities can also initiate VF. Early afterdepolarizations (EADs) — extra depolarizations during Phase 2 or 3 of the action potential — arise when repolarization is prolonged (as in Long QT Syndrome) and can trigger torsades de pointes, which may degenerate into VF. Delayed afterdepolarizations (DADs) — abnormal calcium release from overloaded sarcoplasmic reticulum during diastole — underlie catecholaminergic triggered arrhythmias such as CPVT.

Back to Table of Contents

Underlying Substrates and Causes

Understanding why VF occurred is as important as resuscitating the patient — it determines the long-term management plan and risk of recurrence.

Ischemic Heart Disease

Coronary artery disease is the most common substrate for VF in adults over 40. Acute myocardial infarction (MI) creates acute ischemia that dramatically shortens regional refractory periods, generating the heterogeneity needed for VF. Chronic ischemic scar provides a permanent fixed substrate for re-entry. VF occurring in the first 48 hours of a STEMI (primary VF) carries a different prognosis than VF in the chronic phase of ischemic cardiomyopathy.

Cardiomyopathies

Dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC) all carry elevated VF risk through fibrosis and electrical remodeling. HCM is the most common cause of SCD in young athletes in the United States. ARVC is characterized by fibrofatty replacement of right ventricular myocardium and classically presents with VT/VF triggered by exercise in young adults.

Channelopathies

These are inherited disorders of cardiac ion channels that predispose to VF in hearts that appear structurally normal on imaging:

Long QT Syndrome (LQTS): Prolonged repolarization (long QT on ECG) predisposes to EADs, torsades de pointes, and VF. Multiple genetic subtypes (LQT1–LQT17), most involving potassium or sodium channels. Triggers vary by subtype: LQT1 during exercise/swimming, LQT2 during sudden auditory stimuli, LQT3 during sleep/rest.
Brugada Syndrome: ST elevation in V1–V3 (coved pattern), SCN5A sodium channel mutations in ~20% of cases, VF typically during sleep or fever. Fever can unmask the ECG pattern and precipitate VF; patients should aggressively treat fever and avoid certain drugs (sodium channel blockers, tricyclics — see BrugadaDrugs.com list).
Catecholaminergic Polymorphic VT (CPVT): Exercise- or emotion-induced bidirectional or polymorphic VT degenerating to VF. RyR2 (ryanodine receptor) mutations cause calcium overload in the sarcoplasmic reticulum. Typically presents in children and young adults. Exercise stress testing is the diagnostic key.
Short QT Syndrome: Pathologically shortened QT interval, gain-of-function potassium channel mutations, associated with atrial and ventricular fibrillation.

Wolff-Parkinson-White Syndrome

WPW with rapid atrial fibrillation can degenerate to VF when the accessory pathway has a very short refractory period (shortest pre-excited R-R interval <250 ms). The rapid, irregular conduction through the bypass tract bombards the ventricles at rates exceeding 300 bpm, triggering VF. Ablation of the accessory pathway is curative and eliminates the VF risk.

Other Important Causes

Acute myocarditis: Inflammatory infiltration disrupts normal electrical conduction and can trigger acute VF, particularly in young patients.
Electrolyte disturbances: Severe hypokalemia (K <2.5 mEq/L) and hypomagnesemia lower the threshold for VF by prolonging repolarization and increasing cellular excitability.
Commotio cordis: Blunt, non-penetrating chest wall trauma — most often from a baseball, lacrosse ball, or hockey puck — delivered at the peak of the T wave in young athletes. The mechanical force generates an electrical impulse during the vulnerable period. Survival requires CPR and defibrillation within minutes.
Drug toxicity: Cocaine causes coronary vasospasm and direct sodium channel blockade. Antiarrhythmic drugs themselves can cause proarrhythmia — a sobering lesson from the CAST trial, which showed that Class IC agents (encainide, flecainide) increased mortality when used to suppress PVCs after MI.
Idiopathic VF: Approximately 5–10% of VF survivors have no identifiable structural, ischemic, or genetic cause after full workup. A subset has short-coupled PVCs arising from the Purkinje system (short-coupled variant), and some have early repolarization patterns on ECG. These patients remain a management challenge.
Lightning strike and hypothermia: Hypothermia below 30°C dramatically increases myocardial irritability; below 28°C VF is common and the heart may be refractory to defibrillation until rewarmed.

Back to Table of Contents

Chain of Survival

The American Heart Association's chain of survival describes the sequence of actions that maximize survival from out-of-hospital cardiac arrest (OHCA). Each link is critical; a break in any link substantially reduces the chance of survival.

Recognition and activation of emergency services: Bystanders must recognize that a person has collapsed without a pulse or normal breathing and call 911 immediately. Dispatcher-assisted CPR instructions can bridge the gap until EMS arrives.
Early bystander CPR: Chest compressions keep oxygenated blood flowing to the brain and heart during VF, buying time for defibrillation. Bystander CPR doubles or triples survival rates from OHCA. Tragically, only 30–40% of OHCA victims receive bystander CPR in real-world settings — a major gap that community training programs aim to close.
Early defibrillation: This is the definitive treatment for VF. Survival decreases by 7–10% for every minute that defibrillation is delayed. AED (automated external defibrillator) programs in airports, schools, stadiums, and other public spaces are designed to close this gap. AEDs are safe, simple to use, and are designed to be operated by untrained bystanders — they will not shock a patient in a normal rhythm.
Advanced EMS care: Paramedics provide advanced airway management, intravenous access, and ACLS drugs, and begin post-resuscitation care.
Advanced hospital care: Cardiac catheterization laboratory activation, targeted temperature management, hemodynamic support, and intensive neurological care determine whether a resuscitated patient survives to hospital discharge with good neurological function.

Overall survival to hospital discharge from OHCA averages approximately 10% in the United States, though rates at centers with mature resuscitation systems and robust post-cardiac arrest care programs approach 20–30%. Among hospital survivors, approximately 80% achieve good neurological outcomes (Cerebral Performance Category 1 or 2).

Back to Table of Contents

CPR Technique

High-quality CPR is the backbone of resuscitation — every second of high-quality chest compressions matters. The 2020 AHA CPR and ECC guidelines provide the current standard.

For Untrained Bystanders

Compression-only CPR (hands-only CPR) is strongly recommended for bystanders who have not been trained in CPR or who are not confident in their ability to perform ventilations. Push hard and fast in the center of the chest at a rate of 100–120 compressions per minute until EMS arrives or an AED is used. Compression-only CPR is nearly as effective as CPR with rescue breaths in the first few minutes after cardiac arrest, when residual oxygen in the blood can sustain some circulation.

For Trained Rescuers

Ratio: 30 compressions followed by 2 rescue breaths (30:2) until an advanced airway is placed, after which compressions continue at 100–120/min with one breath every 6 seconds (10 breaths/min) without pausing for breaths.
Rate: 100–120 compressions per minute. Use a metronome or musical cue if needed (classic recommendation: "Stayin' Alive" by the Bee Gees is 103 bpm).
Depth: At least 2 inches (5 cm) in adults; avoid exceeding 2.4 inches (6 cm) to minimize rib fractures. Inadequate depth is one of the most common CPR errors.
Full chest recoil: Allow the chest to fully recoil between compressions — do not lean on the chest. Incomplete recoil impairs venous return and reduces coronary perfusion pressure.
Minimize interruptions: CPR pauses should be less than 10 seconds (e.g., for rhythm checks, defibrillation). CPR fraction (the proportion of resuscitation time with compressions occurring) should exceed 60%, ideally 80%.
Avoid hyperventilation: Excessive ventilation increases intrathoracic pressure, reduces venous return, and worsens outcomes. Do not over-breathe the patient.

Mechanical CPR Devices

Devices such as the LUCAS (Lund University Cardiac Arrest System) and AutoPulse provide consistent automated compressions for prolonged resuscitation or during transport and procedures. They are particularly useful in settings where sustained manual CPR is impractical, such as during cardiac catheterization or while establishing ECMO for refractory VF.

CPR-First vs. Defibrillate-First

If an AED is immediately available and the collapse was witnessed, defibrillate as soon as possible. If the collapse was unwitnessed or the estimated time to defibrillation exceeds 4–5 minutes, provide 2 minutes of CPR before delivering the first shock. CPR first "primes the pump," improving coronary perfusion pressure and making the myocardium more receptive to defibrillation.

Back to Table of Contents

Defibrillation and ACLS

Defibrillation delivers a large electrical current through the chest that simultaneously depolarizes a critical mass of ventricular myocardium, allowing the sinus node to resume organized pacing. It is the only treatment that directly terminates VF.

AEDs

Automated external defibrillators analyze the cardiac rhythm automatically and deliver a shock if VF or pulseless VT is detected. Modern AEDs use biphasic waveforms and provide step-by-step voice instructions. After delivering a shock, immediately resume CPR — do not check the pulse first. If the shock converted VF to a perfusing rhythm, CPR will not cause harm and delays checking for ROSC by only 2 minutes; if it did not convert, the patient still needs compressions.

Manual Defibrillation

In-hospital defibrillators typically use biphasic waveforms. Initial energy dose is 200 J (biphasic); subsequent shocks may be escalated to 200–360 J depending on device recommendations. Older monophasic defibrillators use 360 J for all shocks. After each shock, immediately resume CPR for 2 minutes before checking rhythm.

ACLS Drug Therapy

Drugs are adjuncts to CPR and defibrillation — they do not independently convert VF to a perfusing rhythm.

Epinephrine 1 mg IV/IO every 3–5 minutes: The primary ACLS vasopressor. Alpha-adrenergic vasoconstriction increases aortic diastolic pressure and coronary perfusion pressure during CPR, improving the chance of ROSC. The PARAMEDIC2 trial showed that epinephrine significantly increased ROSC and 30-day survival but did not improve neurologically favorable survival — a nuanced finding that has generated ongoing debate.
Amiodarone 300 mg IV/IO (or lidocaine 1.5 mg/kg as an alternative): Administered after the 3rd defibrillation shock in shock-refractory VF. Amiodarone has been shown to improve rates of survival to hospital admission (though not necessarily to discharge) in refractory VF. A second dose of 150 mg may be given.
Magnesium 2 g IV/IO: Reserved for torsades de pointes or suspected hypomagnesemia-induced VF. Not recommended as a routine ACLS drug for all-cause VF.
Sodium bicarbonate: Used selectively for hyperkalemia-induced VF, tricyclic antidepressant overdose (wide QRS with sodium channel blockade), or prolonged arrest with severe acidosis. Routine bicarbonate in cardiac arrest is not recommended and may worsen outcomes through CO2 generation and paradoxical intracellular acidosis.

Extracorporeal CPR (ECPR)

For patients in refractory VF (typically defined as 3 or more failed defibrillation attempts), who present to or are in a hospital with an ECMO program, extracorporeal membrane oxygenation can provide circulatory support while the underlying cause is identified and treated. ECPR restores organ perfusion mechanically while definitive therapies (PCI for MI, cardioversion with temperature optimization, ablation for electrical storm) are applied. Emerging evidence supports ECPR for selected refractory in-hospital VF cases.

Back to Table of Contents

Post-ROSC Care

Return of spontaneous circulation (ROSC) is not the finish line — it is the beginning of a critical phase of care. Most post-arrest deaths occur in the first 72 hours due to post-cardiac arrest syndrome: a combination of brain injury, myocardial dysfunction, systemic ischemia-reperfusion injury, and the underlying pathology that caused the arrest.

Targeted Temperature Management (TTM)

Therapeutic hypothermia gained landmark evidence from the 2002 HACA trial (NEJM, PMID 11856793), which showed that cooling comatose cardiac arrest survivors to 32–34°C for 24 hours significantly improved neurological outcomes and 6-month survival compared to normothermia. This established TTM as a standard of post-arrest care.

The 2013 TTM trial (PMID 24237006) compared 33°C vs. 36°C in 939 patients and found no significant difference in mortality or neurological outcome between the two temperatures. This nuanced result shifted practice toward targeting 36°C with strict fever prevention rather than deeper hypothermia, which carries risks of arrhythmias, coagulopathy, and infection.

Current evidence from the 2021 TTM2 trial suggests that controlled normothermia (37°C with active fever prevention, targeting <37.7°C) may be non-inferior to hypothermia (33°C) for neurological outcomes. Regardless of target temperature, actively preventing fever remains essential — hyperthermia above 37.7°C is clearly harmful to the injured brain and must be aggressively treated with antipyretics and cooling.

Coronary Revascularization

For post-arrest patients with ST elevation on ECG (STEMI), immediate coronary angiography and PCI is standard care and improves survival. For comatose survivors without ST elevation, the optimal timing of angiography is debated; the COACT trial (2019) found no benefit to immediate vs. delayed angiography in non-STEMI post-arrest patients, but clinical judgment remains important in individual cases with suspected ischemic etiology.

Hemodynamic and Respiratory Support

Vasopressors (norepinephrine) to maintain MAP >65 mmHg; intra-aortic balloon pump or percutaneous mechanical support (Impella) for cardiogenic shock.
Target arterial oxygen saturation 94–98% — avoid hyperoxia, which worsens reperfusion injury to the brain.
Target PaCO2 35–45 mmHg — avoid hypocapnia (cerebral vasoconstriction) and hypercapnia.
Blood glucose 7.8–10 mmol/L (140–180 mg/dL) — avoid both hypoglycemia and severe hyperglycemia.

Neurological Monitoring and Neuroprognostication

EEG monitoring detects subclinical seizures, which are common after cardiac arrest and worsen neurological outcomes. Seizures should be treated aggressively. Neuroprognostication — predicting who will have a good vs. poor neurological outcome — should not be performed before 72 hours post-arrest (longer if hypothermia was used, since it slows drug metabolism and neurological recovery). Multimodal assessment includes:

Clinical exam: absent pupillary reflexes, absent corneal reflexes at 72 hours
Electrodiagnostics: absent bilateral N20 cortical responses on somatosensory evoked potentials (SSEPs), burst-suppression or isoelectric EEG
Biomarkers: markedly elevated neuron-specific enolase (NSE >60–90 µg/L at 48–72 hours)
Imaging: CT showing diffuse cerebral edema (sulcal effacement, gray-white ratio <1.2); MRI showing extensive diffusion restriction

No single test is perfectly predictive; decisions about withdrawal of life-sustaining treatment require convergence of multiple poor-prognosis markers and should involve multidisciplinary ethics consultation.

Back to Table of Contents

ICD Therapy and Long-term Management

Surviving a VF arrest without a correctable cause is an indication for an implantable cardioverter-defibrillator (ICD) in virtually all patients. The ICD continuously monitors the cardiac rhythm and delivers a high-energy shock within seconds of detecting VF — providing the same life-saving therapy as a defibrillator, but automatically and without any delay.

Secondary Prevention ICD

All survivors of VF arrest without a fully reversible cause (transient ischemia from acute MI treated immediately, electrolyte disturbance corrected, etc.) should receive an ICD. Secondary prevention trials (AVID, CIDS, CASH) collectively demonstrated a 20–28% relative risk reduction in total mortality with ICD vs. antiarrhythmic drug therapy.

The subcutaneous ICD (S-ICD) is an alternative for patients who do not require cardiac pacing or resynchronization therapy. The S-ICD avoids intravenous leads entirely — the shock electrode is tunneled subcutaneously — eliminating the risks of lead perforation, lead fracture, and subclavian vein thrombosis. It is particularly attractive in young patients with channelopathies who may live with the device for decades.

Primary Prevention ICD

ICDs are also recommended for patients at high risk of first VF who have not yet had a cardiac arrest:

SCD-HeFT trial (PMID 15753115): ICD therapy reduced all-cause mortality by 23% vs. placebo in patients with LVEF ≤35% and NYHA Class II–III heart failure, regardless of etiology (ischemic or nonischemic). This established EF ≤35% as the primary criterion for primary prevention ICD in cardiomyopathy.
MADIT-II trial: ICD reduced mortality in post-MI patients with EF ≤30%.
High-risk HCM (maximal wall thickness >30mm, family history of SCD, unexplained syncope, NSVT, abnormal blood pressure response to exercise).
High-risk channelopathies: symptomatic LQTS (syncope or VT despite beta-blockers), Brugada with prior cardiac arrest or spontaneous Type 1 pattern with syncope, CPVT refractory to beta-blockers plus flecainide.

Antiarrhythmic Drug Therapy

Beta-blockers: First-line for LQTS (reduce adrenergic triggers for EADs) and CPVT (blunt catecholamine-induced DADs and triggered activity). Nadolol is preferred over metoprolol for both conditions. Left cardiac sympathetic denervation is a surgical option for drug-refractory cases.
Quinidine: Class IA sodium and potassium channel blocker with a long history in cardiac arrhythmias. Counterintuitively useful in Brugada syndrome (blocks the Ito current that creates the characteristic ST elevation) and idiopathic short-coupled VF. Amiodarone is reserved for ICD storm (multiple appropriate shocks in 24 hours).
Flecainide: Added to beta-blockers in CPVT — acts by blocking ryanodine receptor-mediated calcium leak. A second flecainide mechanism (use-dependent sodium channel block) paradoxically suppresses CPVT-triggered arrhythmias.

Catheter Ablation

For patients with idiopathic VF driven by short-coupled PVCs originating from the Purkinje fiber network, catheter ablation targeting the PVC trigger has been shown to dramatically reduce or eliminate VF recurrences. This is particularly effective when the triggering PVC has a consistent, identifiable morphology. Epicardial ablation over the right ventricular outflow tract and inferior right ventricle can reduce VF inducibility in Brugada syndrome, though long-term efficacy data are still accumulating.

Lifestyle Modifications

Specific risk-factor avoidance is tailored to the underlying cause: patients with LQTS must avoid QT-prolonging drugs (a continuously updated list is maintained at CredibleMeds.org); patients with Brugada syndrome must aggressively treat fever (antipyretics at first sign of illness), avoid implicated drugs, and abstain from heavy alcohol; patients with CPVT must avoid intense competitive exercise and manage emotional stress. Genetic testing and cascade screening of first-degree relatives is essential for all inherited channelopathies.

Back to Table of Contents

Prognosis and Neurological Outcomes

The prognosis after VF arrest is determined by two largely independent questions: Did the heart survive? and Did the brain survive? While ICD therapy has dramatically reduced the risk of VF recurrence, it is neurological outcome that most determines a patient's quality of life.

Survival Statistics

Overall survival to hospital discharge from out-of-hospital VF arrest averages 10–12% in large population registries. Survival is substantially better in favorable scenarios: witnessed arrest by a bystander who performs CPR, early AED use, short time from collapse to first shock. In settings with robust public AED programs and high bystander CPR rates (e.g., Seattle, WA; the Netherlands), survival rates approach 20–30%.

For in-hospital VF, survival is higher — approximately 25–30% — because defibrillation can be delivered faster and post-resuscitation care is immediately available.

Neurological Outcome

Neurological outcome is measured by the Cerebral Performance Category (CPC) scale: CPC 1 (normal or near-normal neurological function), CPC 2 (moderate disability, still independent), CPC 3 (severe disability), CPC 4 (vegetative state), CPC 5 (death). Among patients who survive to hospital discharge, approximately 50% achieve CPC 1–2 (good neurological outcome), though this proportion improves with better post-arrest care systems.

The strongest predictors of good neurological outcome are: witnessed arrest, bystander CPR initiated immediately, short time-to-first-shock (<5 minutes), initial shockable rhythm (VF vs. asystole/PEA), and early ROSC. The landmark HACA trial (2002, PMID 11856793) demonstrated that therapeutic hypothermia increased the proportion of patients with good neurological outcome at 6 months from 26% to 55% in VF cardiac arrest survivors — the most dramatic single intervention in post-arrest care.

Long-term Outcomes with ICD

Among VF survivors who receive an ICD and survive to discharge, 5-year survival exceeds 70% in modern series. The ICD does not prevent VF — it aborts it. Appropriate ICD shocks occur in 20–30% of patients per year; ICD storm (≥3 appropriate shocks in 24 hours) is a serious condition associated with increased mortality and requires urgent evaluation and intensification of antiarrhythmic therapy or ablation.

Psychological sequelae are common: depression, anxiety, and post-traumatic stress disorder affect 30–50% of cardiac arrest survivors and their families. Formal psychological support and cardiac rehabilitation are recommended components of post-arrest care.

Back to Table of Contents

Key Research Papers

Resuscitation and Post-Cardiac Arrest Care

Hypothermia after Cardiac Arrest Study Group (HACA). Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549–556. PMID: 11856793 | DOI: 10.1056/NEJMoa012689
Landmark RCT demonstrating that cooling comatose cardiac arrest survivors to 32–34°C for 24 hours doubled the rate of good neurological outcomes. Established therapeutic hypothermia as standard post-arrest care.
Nielsen N, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013;369(23):2197–2206. PMID: 24237006 | DOI: 10.1056/NEJMoa1310519
TTM trial showing no significant difference in mortality or neurological outcome between 33°C and 36°C. Led to revision of post-arrest cooling targets and emphasis on fever prevention.
Callaway CW, et al. Part 8: Post-Cardiac Arrest Care. 2015 AHA Guidelines Update for CPR and ECC. Circulation. 2015;132(18 Suppl 2):S465–S482. PMID: 26468228 | DOI: 10.1161/CIR.0000000000000262
Comprehensive AHA guidelines covering post-resuscitation care including hemodynamic targets, oxygenation, coronary angiography, and neuroprognostication.

ICD and Primary Prevention

Bardy GH, et al. (SCD-HeFT). Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–237. PMID: 15659722 | DOI: 10.1056/NEJMoa043399
SCD-HeFT demonstrated that ICD reduced all-cause mortality by 23% in patients with LVEF ≤35% and NYHA Class II–III heart failure, establishing the EF threshold for primary prevention ICD implantation.
Priori SG, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793–2867. PMID: 26320108 | DOI: 10.1093/eurheartj/ehv316
Comprehensive European guidelines covering risk stratification, ICD indications, channelopathies, catheter ablation, and sudden death prevention across all substrates.

Channelopathies

Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998;97(5):457–460. PMID: 9490172 | DOI: 10.1161/01.CIR.97.5.457
Seminal paper characterizing the Brugada ECG pattern and its association with sudden death from VF in structurally normal hearts.
Priori SG, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103(2):196–200. PMID: 11208676 | DOI: 10.1161/01.CIR.103.2.196
Identified RyR2 mutations as the genetic basis for CPVT, linking calcium handling abnormalities to exercise-induced polymorphic VT and VF.

Bystander CPR and Chain of Survival

Gräsner JT, et al. EuReCa ONE — 27 Nations, ONE Europe, ONE Registry: A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe. Resuscitation. 2016;105:188–195. PMID: 27321616 | DOI: 10.1016/j.resuscitation.2016.06.004
Pan-European registry documenting wide variation in OHCA survival across countries and demonstrating the association of bystander CPR rates with improved outcomes.
Sasson C, et al. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3(1):63–81. PMID: 20123673 | DOI: 10.1161/CIRCOUTCOMES.109.889576
Meta-analysis of 142 studies quantifying the impact of witnessed arrest, bystander CPR, shockable rhythm, and time-to-defibrillation on survival from OHCA.

Special Causes and Mechanisms

Maron BJ, et al. Commotio cordis — ventricular fibrillation and death from low-energy chest-wall impact in a precordial thump area. Lancet. 1995;345(8944):519–522. PMID: 7776779 | DOI: 10.1016/S0140-6736(95)90454-7
Described commotio cordis — VF from low-energy blunt chest impact during the T-wave vulnerable period — in competitive athletes without structural heart disease.
Haïssaguerre M, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–666. (Context: Haïssaguerre also pioneered VF ablation research — see below.) PMID: 9725923
Foundational work on ectopic trigger mapping from this group; Haïssaguerre subsequently demonstrated that idiopathic VF can be ablated by targeting short-coupled Purkinje triggers.
Nolan JP, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. Resuscitation. 2008;79(3):350–379. PMID: 18963492 | DOI: 10.1016/j.resuscitation.2008.09.017
Comprehensive review defining post-cardiac arrest syndrome and establishing the framework for ICU-based post-resuscitation care including temperature management, hemodynamic targets, and neuroprognostication.